Bouthors ASD, Mercier FJ, Grouin JM, et al. - Researchers conducted a multicentre, double‐blind, randomized placebo‐controlled trial with the aim to determine the benefits and safety of early human fibrinogen concentrate in postpartum haemorrhage (PPH) management. Patients with persistent PPH after vaginal delivery requiring a switch from oxytocin to prostaglandins were administered either 3 g fibrinogen concentrate or placebo within 30 min after introduction of prostaglandins. Of 437 included patients, 224 received FC and 213 placebo. In line with outcomes from previous placebo‐controlled studies, outcomes herein suggest that early and systematic administration of 3 g fibrinogen concentrate did not lower blood loss, transfusion needs, and postpartum anaemia, but averted plasma fibrinogen reduction without any subsequent thromboembolic events.